SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001437749-22-006759
Filing Date
2022-03-18
Accepted
2022-03-18 17:41:19
Documents
9
Period of Report
2022-04-14

Document Format Files

Seq Description Document Type Size
1 FORM PRE 14A dffn20220318_pre14a.htm PRE 14A 323940
2 dffn20220318_pre14aimg001.gif GRAPHIC 6957
3 dffn20220318_pre14aimg002.jpg GRAPHIC 7477
4 dffn20220318_pre14aimg003.jpg GRAPHIC 7477
5 dffn20220318_pre14aimg004.jpg GRAPHIC 1061
6 dffn20220318_pre14aimg005.jpg GRAPHIC 1061
7 dffn20220318_pre14aimg006.jpg GRAPHIC 3029
8 dffn20220318_pre14aimg007.jpg GRAPHIC 2625
9 dffn20220318_pre14aimg008.jpg GRAPHIC 3059
  Complete submission text file 0001437749-22-006759.txt   371586
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37942 | Film No.: 22753657
SIC: 2834 Pharmaceutical Preparations